In summary, the current study shows that upregulated TUBA1C is related to poor prognosis in cancer patients, is associated with a higher tumour grade, affects tumour sensitivity to and the efficacy of ICI therapy, influences immune cell infiltration in the TME, and interacts with immune-associated genes and pathways in cancers. The gene discussed is TUBA1C; the disease is cancer.